Navigation Links
Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
Date:2/23/2012

operations if it is unable to  raise adequate funding; if the development of its drug candidates, including clinical trials of TELINTRA or TELCYTA, is delayed or unsuccessful, if Telik does not enter into collaborative arrangements to advance its programs, the rate of product development will be delayed and expenditures may increase; if Telik is delisted from the Nasdaq Capital Market, its ability to raise additional financing and the liquidity of its common stock could be adversely affected. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended September 30, 2011. Telik does not undertake any obligation to update forward looking statements contained in this press release.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Twelve Months EndedDecember 31,December 31,2011201020112010Operating costs and expenses:Research and development

$
,1022,838$
5,566$  11,040General and administrative

1,4012,3746,4919,230Facility exit costs

-5,360-5,360Restructuring costs

-425-425Total operating costs and expenses

2,50310,99712,05726,055Loss from operations

(2,503)(10,997)(12,057)(26,055)Interest and other income (expense), net

41,201351,333Net loss

$
(2,499)$
(9,796)$ (12,022)$ (24,722)Basic and diluted net loss per share

$
(0.05)$
(0.18)$
(0.22)$
(0.46)Weighted average shares used to calculate basic and diluted net loss per share

54,14253,61453,93953,539Selected Balance Sheet
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
2. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
3. Telik Announces Third Quarter 2011 Financial Results
4. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
5. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
7. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
8. Telik Announces First Quarter 2011 Financial Results
9. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
10. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
11. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... Reports Significantly More Patients Treated,with Taxotere(R)-Based ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- ... maintained long-term efficacy as a treatment ... to the three-year updated results of ...
... - Schering-Plough Corp. announced results,from a Phase ... (pegylated liposomal doxorubicin hydrochloride),significantly prolonged time to ... with infrequent and manageable clinical,toxicity after first-line ... 43rd Annual Meeting of the American Society ...
Cached Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... ... Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness ... into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have ... the Apple AppStore. , The app is designed to track various metrics of ... tool to view personal health and use this information for positive behavior modification. Lume ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... When the ... stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . ... in process. , To commemorate introduction of this new type of sod, Super-Sod is ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... May 31 Telik, Inc. (Nasdaq: TELK ... of the American Society of Clinical Oncology (ASCO) in ... randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination ... second-line therapy in platinum refractory or resistant ovarian cancer. ...
... - New research quantifies the precise effects of environmental ... studies being presented this week during Digestive Disease Week ... that the environment and alcohol intake can affect GI ... future research. DDW is the largest international gathering of ...
... breast tumor treatments called ,exciting, , , SUNDAY, May 31 ... nice to be anywhere," singer and actress Olivia Newton-John, ... one of the world,s largest gatherings of cancer specialists ... news briefing on advances and insights in breast and ...
... seek alternatives to SSRIs for hot flashes, studies suggest ... antidepressants that many breast cancer survivors use to dampen ... boost the odds of the disease,s return, new research ... the American Society of Clinical Oncology,s annual meeting, in ...
... cyclists to start San Francisco-to-Los Angeles ride May 31SAN ... 2,150 bicyclists from 41 states and 14 nations will ... route to Los Angeles as participants in the colorful ... 545-mile trek is expected to raise $10.5 million to ...
... Red technology (NIR) delivers revolutionary pain free hair removal. ... UK to offer genuine groundbreaking hair removal laser technology ... 31 Transform, the UK,s largest group of plastic ... of the first in the UK to install the ...
Cached Medicine News:Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 2Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 3Health News:Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer 4Health News:To what extent can environmental pollutants and alcohol affect GI health? 2Health News:To what extent can environmental pollutants and alcohol affect GI health? 3Health News:New Insights, Inroads Against Breast, Ovarian Cancers 2Health News:New Insights, Inroads Against Breast, Ovarian Cancers 3Health News:New Insights, Inroads Against Breast, Ovarian Cancers 4Health News:New Insights, Inroads Against Breast, Ovarian Cancers 5Health News:Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer 2Health News:Some Antidepressants May Thwart Tamoxifen's Effect on Breast Cancer 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 4Health News:Pain-Free, Hair-Free System Set to Transform Hair Removal 2Health News:Pain-Free, Hair-Free System Set to Transform Hair Removal 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: